Get started

Tgtherapeutics

TG Therapeutics (TGTX) – Biotech Innovation & Global ExpansionCompany Overview: TG Therapeutics NASDAQ:TGTX is a biotech leader focused on novel cancer and autoimmune treatments, gaining momentum as an IBD Leaderboard and IBD 50 Top 10 Growth Stock. Key Catalysts: Regulatory Approvals & Expansion 🌍 BRIUMVI secured approvals in Europe & the UK, unlocking new revenue streams in key markets. Strong Profitability & Growth 💰 88.3% gross margin ensures sustainable reinvestment into R&D and future pipeline advancements. High-Growth Stock Recognition 📊 Technical strength is validated by its inclusion in top-performing stock lists, signaling strong investor confidence. Investment Outlook: Bullish Case: We are bullish on TGTX above $34.00-$35.00, driven by global expansion, financial strength, and biotech leadership. Upside Potential: Our price target is $55.00-$56.00, supported by continued innovation and market penetration. 🔥 TG Therapeutics – Pioneering the Future of Cancer Treatment. #TGTX #Biotech #GrowthStocks
NASDAQ:TGTXLong
by Richtv_official
TG Therapeutics (TGTX) Analysis Company Overview: TG Therapeutics NASDAQ:TGTX is a biopharmaceutical company focused on developing and commercializing innovative treatments for B-cell diseases. The company's recent FDA approval of BRIUMVI for relapsing multiple sclerosis (RMS) marks a significant milestone, positioning TG Therapeutics to capitalize on a high-demand therapeutic area. Key Developments: FDA Approval of BRIUMVI: The approval of BRIUMVI for relapsing multiple sclerosis opens access to a substantial market, with nearly 1 million individuals in the U.S. affected by RMS. This provides a significant revenue opportunity, with BRIUMVI offering a new treatment option that has shown favorable efficacy, safety, and convenient dosing compared to existing therapies. Positive Market Reception: CEO Michael S. Weiss has expressed strong confidence in BRIUMVI's potential, noting positive feedback from both healthcare providers and patients. The drug's unique value proposition lies in its twice-yearly dosing, which is more convenient than the monthly or quarterly regimens offered by competitors, enhancing patient compliance and satisfaction. Pipeline and Future Growth: The successful launch of BRIUMVI is a testament to TG Therapeutics' ability to introduce novel treatments. This sets a strong foundation for future developments in B-cell disease therapies, as the company explores additional indications and expands its pipeline. BRIUMVI's performance in the market could pave the way for further advancements in TG Therapeutics' product offerings. Investment Outlook: Bullish Outlook: We are bullish on TGTX above the $21.00-$22.00 range, driven by the strong initial reception of BRIUMVI and its potential to capture a significant share of the RMS market. Upside Potential: Our price target for TG Therapeutics is set at $34.00-$35.00, reflecting the expected revenue growth from BRIUMVI and the company's strategic positioning in the biopharma sector. 🚀 TGTX—Leading the Way in B-cell Disease Therapies! #BiopharmaInnovation #MultipleSclerosis #NewTreatmentOptions
NASDAQ:TGTXLong
by Richtv_official
TG Therapeutics. Boom! TGTXWe are moving up. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe!
NASDAQ:TGTXLong
by Rykin_Capital